AZ US agreement on Seroquel m

RNS Number : 9128K
AstraZeneca PLC
28 April 2010
 



ASTRAZENECA FINALISES US AGREEMENT ON SEROQUEL MARKETING

 

AstraZeneca announced today that the company has finalised a previously announced agreement in principle with federal and state entities in the United States to resolve civil allegations relating to the company's past marketing and promotion of its atypical antipsychotic, SEROQUEL.

 

The final agreement is with the United States Attorney's Office for the Eastern District of Pennsylvania, the United States Department of Justice, various other federal agencies, the National Association of Medicaid Fraud Control Units (NAMFCU) and the two qui tam relators.

 

Under the terms of the agreement, AstraZeneca denies the allegations but will pay a previously disclosed $520 million that was taken as a reserve in 2009, along with certain accrued interest. A portion of the payment will be distributed to states participating in the NAMFCU settlement.

 

As part of the settlement, AstraZeneca has entered into a corporate integrity agreement with the Office of Inspector General of the United States Department of Health and Human Services. The corporate integrity agreement will be in effect for five years.

 

 

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines.  As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009.  For more information please visit: www.astrazeneca.com

 

 

Media Enquiries UK:



Neil McCrae

+44 20 7304 5045  (24 hours)


Chris Sampson

+44 20 7304 5130  (24 hours)


Sarah Lindgreen

+44 20 7304 5033  (24 hours)


Abigail Baron

+44 20 7304 5034  (24 hours)





Investor Enquiries UK:



Jonathan Hunt

+44 207 304 5087

mob: +44 7775 704032

Karl Hård

+44 207 304 5322

mob: +44 7789 654364

Clive Morris

+44 207 304 5084

mob: +44 7710 031012




Investor Enquiries US:



Ed Seage

+1 302 886 4065

mob: +1 302 373 1361

Jorgen Winroth

+1 212 579 0506

mob: +1 917 612 4043

 

 

28 April 2010

 

- ENDS -


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRKKODPCBKDFQB

Companies

AstraZeneca (AZN)
Investor Meets Company
UK 100